Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

A descrição da empresa é mostrada em inglês.

Visitar site →

Estatísticas Principais

Capitalização: $2.79M
Índice P/L: N/A
Máx. 52 Sem.: $5.60
Mín. 52 Sem.: $0.72
Volume Médio: 332.81K
Beta: 1.87

Dados fornecidos pelo Yahoo Finance via yfinance. Atualizado diariamente.

Informações da Empresa

Indústria: Biotecnologia
Bolsa: NASDAQ
País: United States
Funcionários: 52